These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

291 related items for PubMed ID: 22355276

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP, Huang CK, Chang YJ, Chung CY, Yamashita S, Li L, Lee SO, Yeh S, Chang C.
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [Abstract] [Full Text] [Related]

  • 3. Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling.
    Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S, Chang C.
    Cell Death Dis; 2013 Aug 08; 4(8):e764. PubMed ID: 23928703
    [Abstract] [Full Text] [Related]

  • 4. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9® to Suppress Enzalutamide-resistant Prostate Cancer Progression.
    Wang R, Sun Y, Li L, Niu Y, Lin W, Lin C, Antonarakis ES, Luo J, Yeh S, Chang C.
    Eur Urol; 2017 Nov 08; 72(5):835-844. PubMed ID: 28528814
    [Abstract] [Full Text] [Related]

  • 5. Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C.
    Cancer Lett; 2018 Mar 28; 417():182-191. PubMed ID: 29203251
    [Abstract] [Full Text] [Related]

  • 6. ASC-J9(®), and not Casodex or Enzalutamide, suppresses prostate cancer stem/progenitor cell invasion via altering the EZH2-STAT3 signals.
    Wen S, Tian J, Niu Y, Li L, Yeh S, Chang C.
    Cancer Lett; 2016 Jul 01; 376(2):377-86. PubMed ID: 27045473
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ASC-J9® suppresses prostate cancer cell invasion via altering the sumoylation-phosphorylation of STAT3.
    Lin W, Luo J, Sun Y, Lin C, Li G, Niu Y, Chang C.
    Cancer Lett; 2018 Jul 01; 425():21-30. PubMed ID: 29425687
    [Abstract] [Full Text] [Related]

  • 9. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
    Wen S, Niu Y, Lee SO, Yeh S, Shang Z, Gao H, Li Y, Chou F, Chang C.
    Mol Carcinog; 2016 Dec 01; 55(12):2278-2290. PubMed ID: 26894509
    [Abstract] [Full Text] [Related]

  • 10. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO, Fahrenholtz CD, Burnstein KL.
    Mol Endocrinol; 2012 Dec 01; 26(12):1967-79. PubMed ID: 23023561
    [Abstract] [Full Text] [Related]

  • 11. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.
    Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y.
    Cancer Res; 2009 Mar 15; 69(6):2305-13. PubMed ID: 19244107
    [Abstract] [Full Text] [Related]

  • 12. ASC-J9® suppresses prostate cancer cell proliferation and invasion via altering the ATF3-PTK2 signaling.
    Tian H, Chou FJ, Tian J, Zhang Y, You B, Huang CP, Yeh S, Niu Y, Chang C.
    J Exp Clin Cancer Res; 2021 Jan 04; 40(1):3. PubMed ID: 33390173
    [Abstract] [Full Text] [Related]

  • 13. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 14. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C.
    Cancer Lett; 2019 Mar 01; 444():35-44. PubMed ID: 30248372
    [Abstract] [Full Text] [Related]

  • 15. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.
    Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.
    Proc Natl Acad Sci U S A; 2010 Sep 28; 107(39):16759-65. PubMed ID: 20823238
    [Abstract] [Full Text] [Related]

  • 16. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
    Honda M, Kimura T, Kamata Y, Tashiro K, Kimura S, Koike Y, Sato S, Yorozu T, Furusato B, Takahashi H, Kiyota H, Egawa S.
    Prostate; 2019 Jun 28; 79(9):1043-1052. PubMed ID: 30998834
    [Abstract] [Full Text] [Related]

  • 17. Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage.
    Li L, Xie H, Liang L, Gao Y, Zhang D, Fang L, Lee SO, Luo J, Chen X, Wang X, Chang LS, Yeh S, Wang Y, He D, Chang C.
    Carcinogenesis; 2013 Feb 28; 34(2):257-67. PubMed ID: 23104178
    [Abstract] [Full Text] [Related]

  • 18. Infiltrating mast cells enhance prostate cancer invasion via altering LncRNA-HOTAIR/PRC2-androgen receptor (AR)-MMP9 signals and increased stem/progenitor cell population.
    Li L, Dang Q, Xie H, Yang Z, He D, Liang L, Song W, Yeh S, Chang C.
    Oncotarget; 2015 Jun 10; 6(16):14179-90. PubMed ID: 25895025
    [Abstract] [Full Text] [Related]

  • 19. Preclinical study using androgen receptor (AR) degradation enhancer to increase radiotherapy efficacy via targeting radiation-increased AR to better suppress prostate cancer progression.
    Chou FJ, Chen Y, Chen D, Niu Y, Li G, Keng P, Yeh S, Chang C.
    EBioMedicine; 2019 Feb 10; 40():504-516. PubMed ID: 30692044
    [Abstract] [Full Text] [Related]

  • 20. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
    Dondoo TO, Fukumori T, Daizumoto K, Fukawa T, Kohzuki M, Kowada M, Kusuhara Y, Mori H, Nakatsuji H, Takahashi M, Kanayama HO.
    Anticancer Res; 2017 Jan 10; 37(1):125-134. PubMed ID: 28011482
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.